Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200123, China.
Department of Emergency and Critical Care Medicine, Changzheng Hospital, Second Military Medical University, Shanghai, 200082, China.
Virol J. 2020 Oct 23;17(1):162. doi: 10.1186/s12985-020-01428-5.
We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions.
Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients.
Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions.
In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.
本研究旨在描述庇护医院 220 例非紧急(轻症或普通型)COVID-19 患者的特征,并评估抗病毒药物利巴韦林在其疾病进展中的疗效。
描述基本临床特征,并根据患者的性别、年龄、最高体温评估利巴韦林的疗效。
基本上,男性发热风险和发病症状比女性更高。利巴韦林可加速发热恢复和呼吸道标本中病毒清除,特别是在男性中。利巴韦林还可缩短住院时间,且无明显不良反应。
在回顾性 COVID-19 队列中,性别是影响患者病情的重要因素之一。利巴韦林在这些患者中显示出多种有益作用,特别是在男性中。本研究为理解新发传染病提供了更多的研究启示。